F-star and Christian Doppler Lab in new collaboration

14 July 2016

UK-based biotech F-star has announced the extension of a collaboration and funding arrangement with the Christian Doppler (CD) Laboratory for Innovative Immunotherapeutics at the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria.

F-star, which has partnered with some of pharma’s leading companies, sees the collaboration as key to strengthening its position in immuno-oncology and bispecific antibodies by allowing the company to explore additional applications of its powerful Modular Antibody Technology.

The Cambridge-based company will retain rights to intellectual property arising from work in the lab. It has hailed the collaboration as a great example of UK biopharma leveraging public-private partnerships and build strong academic bridges globally, including in Europe, to drive cutting edge innovation.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK